Skip to content

sajor2000/methodsmith / plugins/methodsmith/skills/method-checklist

method-checklist

Verified

Selects EQUATOR reporting guidelines (CONSORT, STROBE, RECORD, PRISMA, TRIPOD+AI, TARGET, STARD, CLAIM) for a study. Use when the user asks which reporting checklist applies.

references/checklist-snippets/SPIRIT.md

View on GitHub
# SPIRIT 2025 Checklist (Protocols of Randomised Trials)

Use at the protocol stage of an RCT; layer SPIRIT-AI on it when the AI is the trial intervention. SPIRIT 2025 has 34 numbered items (53 rows with lettered sub-items). Item numbers and wording are copied verbatim from Table 1 of the statement (CC BY 4.0) and mirror the checklist that `method-review` validates against at review time. Completed trial reports use CONSORT 2025.

**Primary reference:** Chan AW, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477. doi:10.1136/bmj-2024-081477. PMID: 40294953. PMCID: PMC12035670.

**Source table:** SPIRIT 2025 Table 1, PMC12035670. Licence: CC BY 4.0.

| # | Section | Item | Status | Note |
|---|---------|------|--------|------|
| 1a | Administrative | Title stating the trial design, population, and interventions, with identification as a protocol | ☐ | |
| 1b | Administrative | Structured summary of trial design and methods, including items from the World Health Organization Trial Registration Data Set | ☐ | |
| 2 | Administrative | Version date and identifier | ☐ | |
| 3a | Administrative | Names, affiliations, and roles of protocol contributors | ☐ | |
| 3b | Administrative | Name and contact information for the trial sponsor | ☐ | |
| 3c | Administrative | Role of trial sponsor and funders in design, conduct, analysis, and reporting of trial; including any authority over these activities | ☐ | |
| 3d | Administrative | Composition, roles, and responsibilities of the coordinating site, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable | ☐ | |
| 4 | Open science | Name of trial registry, identifying number (with URL), and date of registration. If not yet registered, name of intended registry | ☐ | |
| 5 | Open science | Where the trial protocol and statistical analysis plan can be accessed | ☐ | |
| 6 | Open science | Where and how the individual de-identified participant data (including data dictionary), statistical code, and any other materials will be accessible | ☐ | |
| 7a | Open science | Sources of funding and other support (eg, supply of drugs) | ☐ | |
| 7b | Open science | Financial and other conflicts of interest for principal investigators and steering committee members | ☐ | |
| 8 | Open science | Plans to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, reporting in trial registry, plain language summary, publication) | ☐ | |
| 9a | Introduction | Scientific background and rationale, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention | ☐ | |
| 9b | Introduction | Explanation for choice of comparator | ☐ | |
| 10 | Introduction | Specific objectives related to benefits and harms | ☐ | |
| 11 | Methods: PPI and design | Details of, or plans for, patient or public involvement in the design, conduct, and reporting of the trial | ☐ | |
| 12 | Methods: PPI and design | Description of trial design including type of trial (eg, parallel group, crossover), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory) | ☐ | |
| 13 | Methods: participants, interventions, outcomes | Settings (eg, community, hospital) and locations (eg, countries, sites) where the trial will be conducted | ☐ | |
| 14a | Methods: participants, interventions, outcomes | Eligibility criteria for participants | ☐ | |
| 14b | Methods: participants, interventions, outcomes | If applicable, eligibility criteria for sites and for individuals who will deliver the interventions (eg, surgeons, physiotherapists) | ☐ | |
| 15a | Methods: participants, interventions, outcomes | Intervention and comparator with sufficient details to allow replication including how, when, and by whom they will be administered. If relevant, where additional materials describing the intervention and comparator (eg, intervention manual) can be accessed | ☐ | |
| 15b | Methods: participants, interventions, outcomes | Criteria for discontinuing or modifying allocated intervention/comparator for a trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) | ☐ | |
| 15c | Methods: participants, interventions, outcomes | Strategies to improve adherence to intervention/comparator protocols, if applicable, and any procedures for monitoring adherence (eg, drug tablet return, sessions attended) | ☐ | |
| 15d | Methods: participants, interventions, outcomes | Concomitant care that is permitted or prohibited during the trial | ☐ | |
| 16 | Methods: participants, interventions, outcomes | Primary and secondary outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome | ☐ | |
| 17 | Methods: participants, interventions, outcomes | How harms are defined and will be assessed (eg, systematically, non-systematically) | ☐ | |
| 18 | Methods: participants, interventions, outcomes | Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see fig 1 of the statement) | ☐ | |
| 19 | Methods: participants, interventions, outcomes | How sample size was determined, including all assumptions supporting the sample size calculation | ☐ | |
| 20 | Methods: participants, interventions, outcomes | Strategies for achieving adequate participant enrolment to reach target sample size | ☐ | |
| 21a | Methods: assignment | Who will generate the random allocation sequence and the method used | ☐ | |
| 21b | Methods: assignment | Type of randomisation (simple or restricted) and details of any factors for stratification. To reduce predictability of a random sequence, other details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions | ☐ | |
| 22 | Methods: assignment | Mechanism used to implement the random allocation sequence (eg, central computer/telephone; sequentially numbered, opaque, sealed containers), describing any steps to conceal the sequence until interventions are assigned | ☐ | |
| 23 | Methods: assignment | Whether the personnel who will enrol and those who will assign participants to the interventions will have access to the random allocation sequence | ☐ | |
| 24a | Methods: assignment | Who will be blinded after assignment to interventions (eg, participants, care providers, outcome assessors, data analysts) | ☐ | |
| 24b | Methods: assignment | If blinded, how blinding will be achieved and description of the similarity of interventions | ☐ | |
| 24c | Methods: assignment | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial | ☐ | |
| 25a | Methods: data and analysis | Plans for assessment and collection of trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of trial instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be accessed, if not in the protocol | ☐ | |
| 25b | Methods: data and analysis | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | ☐ | |
| 26 | Methods: data and analysis | Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be accessed, if not in the protocol | ☐ | |
| 27a | Methods: data and analysis | Statistical methods used to compare groups for primary and secondary outcomes, including harms | ☐ | |
| 27b | Methods: data and analysis | Definition of who will be included in each analysis (eg, all randomised participants), and in which group | ☐ | |
| 27c | Methods: data and analysis | How missing data will be handled in the analysis | ☐ | |
| 27d | Methods: data and analysis | Methods for any additional analyses (eg, subgroup and sensitivity analyses) | ☐ | |
| 28a | Methods: monitoring | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and funder; conflicts of interest and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed | ☐ | |
| 28b | Methods: monitoring | Explanation of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial | ☐ | |
| 29 | Methods: monitoring | Frequency and procedures for monitoring trial conduct. If there is no monitoring, give explanation | ☐ | |
| 30 | Ethics | Plans for seeking research ethics committee/institutional review board approval | ☐ | |
| 31 | Ethics | Plans for communicating important protocol modifications to relevant parties | ☐ | |
| 32a | Ethics | Who will obtain informed consent or assent from potential trial participants or authorised proxies, and how | ☐ | |
| 32b | Ethics | Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable | ☐ | |
| 33 | Ethics | How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial | ☐ | |
| 34 | Ethics | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation | ☐ | |
slack-gif-creatoranthropics/skillsKnowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like "make me a GIF of X doing Y for Slack."Stars: 198kUpdated Claude CodeCodexVerifiedInstall
ponytailDietrichGebert/ponytailLazy senior dev mode for any coding task: the smallest change that fully solves it, and a reply a busy human understands in one read.Stars: 196kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailHarvest every shortcut: comment into one debt ledger, so deferrals get tracked instead of forgotten. One-shot report.Stars: 196kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailList every `shortcut:` comment (and older `ponytail:` ones) as a debt ledger. One-shot report, changes nothing. Use for "ponytail debt", "what did ponytail defer", "list the shortcuts", /ponytail-debt.Stars: 196kUpdated Claude CodeCodexVerifiedInstall